PCM
LVTX

Pinz Capital Management’s LAVA Therapeutics LVTX Stock Holding History

Pinz Capital Management’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,900
Closed -$393K – 490
2021
Q1 		$393K Buy
+25,900
New +$356K 0.1% 99

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pinz Capital Management's LVTX Position: Q2 2021 in Review

Pinz Capital Management sold out of LAVA Therapeutics (LVTX) in Q2 2021, closing a stake of 25,900 shares — an estimated $393K sold.

Pinz Capital Management first reported a position in LVTX in Q1 2021 and held it in 1 quarter. The position peaked at $393K in Q1 2021. 18 funds tracked by Wall St. Rank hold LVTX as of Q2 2021.

  • Pinz Capital Management reported no remaining LAVA Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Pinz Capital Management sold 25,900 LAVA Therapeutics shares in Q2 2021, an estimated $393K.
  • Pinz Capital Management first reported a position in LAVA Therapeutics in Q1 2021 and held it in 1 quarter.
  • Pinz Capital Management's LAVA Therapeutics position peaked at $393K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2021.

Based on Pinz Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.